[go: up one dir, main page]

GT199900039A - STATIN-MMP INHIBITOR COMBINATIONS. - Google Patents

STATIN-MMP INHIBITOR COMBINATIONS.

Info

Publication number
GT199900039A
GT199900039A GT199900039A GT199900039A GT199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A GT 199900039 A GT199900039 A GT 199900039A
Authority
GT
Guatemala
Prior art keywords
statin
mmp inhibitor
inhibitor combinations
frague
fleasure
Prior art date
Application number
GT199900039A
Other languages
Spanish (es)
Inventor
Roger Schofield Newton
Bruce David Roth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900039A publication Critical patent/GT199900039A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ESTA INVENCIÒN PROPORCIONA UN MÈTODO DE TRATAMIENTO Y PREVENCIÒN DE LA INSUFICIENCIA CARDÌACA Y OTRAS ENFERMEDADES VASCULARES EN UN MAMÌFERO, QUE COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN INHIBIDOR DE METALOPROTEINASA DE MATRIZ JUNTO CON UNA ESTATINA (VER FÒRMULA I & II ADJUNTAS, LAS LETRAS "A" Y "R" REPRESENTAN POSIBLES GRUPOS FUNCIONALES QUE PUEDEN SER SUSTITUIDOS Y CUYO LISTADO ESPECÌFICO PUEDE LEERSE EN EL DOCUMENTO ORIGINAL).THIS INVENTION PROVIDES A METHOD OF TREATMENT AND PREVENTION OF HEART FAILURE AND OTHER VASCULAR DISEASES IN A MAMMAL, WHICH INCLUDES ADMINISTERING AN EFFECTIVE AMOUNT OF A & AJURY FROM A FRAGUE OF LIFE FROM A MATRIA FLEASURE "AND" R "REPRESENT POSSIBLE FUNCTIONAL GROUPS THAT CAN BE REPLACED AND WHOSE SPECIFIC LISTING CAN BE READ IN THE ORIGINAL DOCUMENT).

GT199900039A 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS. GT199900039A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
GT199900039A true GT199900039A (en) 2000-09-06

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900039A GT199900039A (en) 1998-03-17 1999-03-16 STATIN-MMP INHIBITOR COMBINATIONS.

Country Status (18)

Country Link
EP (1) EP1063991A1 (en)
JP (1) JP2002506818A (en)
KR (1) KR20010041916A (en)
AR (1) AR018113A1 (en)
AU (1) AU1591699A (en)
BR (1) BR9815745A (en)
CA (1) CA2309588A1 (en)
CO (1) CO5070670A1 (en)
GT (1) GT199900039A (en)
HN (1) HN1999000029A (en)
MY (1) MY140504A (en)
NZ (1) NZ505994A (en)
PA (1) PA8469001A1 (en)
PE (1) PE20000348A1 (en)
SV (1) SV1999000026A (en)
UY (1) UY25436A1 (en)
WO (1) WO1999047138A1 (en)
ZA (1) ZA992106B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636783T2 (en) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION
CZ294063B6 (en) * 1996-05-17 2004-09-15 Warner-Lambert Company Biphenyl sulfonamide, use thereof and pharmaceutical composition in which it is comprised
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (en) * 1997-08-29 2000-01-29 COMBINATION THERAPY.

Also Published As

Publication number Publication date
AU1591699A (en) 1999-10-11
SV1999000026A (en) 2000-01-18
MY140504A (en) 2009-12-31
BR9815745A (en) 2000-11-14
ZA992106B (en) 1999-09-30
KR20010041916A (en) 2001-05-25
EP1063991A1 (en) 2001-01-03
HN1999000029A (en) 1999-09-29
WO1999047138A1 (en) 1999-09-23
CA2309588A1 (en) 1999-09-23
PE20000348A1 (en) 2000-05-22
PA8469001A1 (en) 2002-09-17
AR018113A1 (en) 2001-10-31
NZ505994A (en) 2003-10-31
CO5070670A1 (en) 2001-08-28
JP2002506818A (en) 2002-03-05
UY25436A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
EA200100572A1 (en) METHOD OF APPLICATION OF CYCLOOXIGENASE-2 INHIBITOR AND ONE OR MULTIPLE ANTITUMOR MEDICINES AS A COMBINED METHOD OF MEDICAL EXPOSURE IN THE TREATMENT OF NEOPLASIA
BR9812879A (en) Ophthalmic lens
PT971713E (en) USE OF COLINESTERASE INHIBITORS FOR TREATMENT OF ATENTION DISORDERS
TR200000756T2 (en) Treatment of behavioral disorder.
PL317425A1 (en) Combinations of retroviral protease inhibitors
EP0934064A4 (en) THROMBIN INHIBITORS
PT1427409E (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
GT199800177A (en) EFFECTIVE COMBINATION FOR THE TREATMENT OF IMPOTENCE.
CO4600725A1 (en) SYNERGISTIC INSECTICIDE COMPOSITIONS
GT199900039A (en) STATIN-MMP INHIBITOR COMBINATIONS.
DE69625230D1 (en) thrombin inhibitors
NO984160L (en) Procedure for the treatment or prevention of interstitial cystitis
PT1133296E (en) NEW NICERGOLIN THERAPEUTIC APPLICATION
NO20005548L (en) Mykobakterieinhibitorer
IT8919735A0 (en) PROCEDURE FOR THE REDUCTION OF CODE FROM INDUSTRIAL OR URBAN WASTEWASTE.
DE68920757D1 (en) Lysyl oxidase inhibitors.
NO995849D0 (en) Aldehyde-free disinfectant for surfaces and instruments
AR034375A1 (en) COMBINATION OF A PTPASA INHIBITOR AND A SULFONILE AGENT
BR0112460A (en) Method for sepsis treatment
BR9612549A (en) Method for treating excessive aggression
DK0828483T3 (en) Use of tropolone derivatives as inhibitors of the enzyme inositol monophosphatase
PT1133297E (en) NEW THERAPEUTIC APPLICATION OF 1,6-DIMETHYL-8BETAHYDROXYMETHYL-10ALFA-METHOXERGOLINE
ECSP951559A (en) 5-LIPOXIGENASE INHIBITORS
MX9707198A (en) Terminal carboxy or tetrazole groups containing dialkyl ethers.
ECSP992885A (en) STATIN-MMP INHIBITOR COMBINATIONS